Immune checkpoint inhibitors (ICIs) blocking cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed cell death 1 (PD-1) or its ligand of programmed cell death ligand 1(PD-L1) to enhance anti-tumor immunity has made a major breakthrough in cancer treatment. Here, PDCD1 is linked to neoplasm.